FIA
DCPH

FNY Investment Advisers’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

FNY Investment Advisers’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-500
Closed -$19K – 1098
2018
Q3 		$19K Sell
500
-500
-50% -$18.5K ﹤0.01% 466
2018
Q2 		$39K Buy
+1,000
New +$29.4K 0.02% 307

Other funds holding DCPH

NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

FNY Investment Advisers's DCPH Position: Q4 2018 in Review

FNY Investment Advisers sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q4 2018, closing a stake of 500 shares — an estimated $19K sold.

FNY Investment Advisers first reported a position in DCPH in Q2 2018 and held it in 2 quarters. The position peaked at $39K in Q2 2018. 78 funds tracked by Wall St. Rank hold DCPH as of Q4 2018.

  • FNY Investment Advisers reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • FNY Investment Advisers sold 500 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q4 2018, an estimated $19K.
  • FNY Investment Advisers first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
  • FNY Investment Advisers's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $39K in Q2 2018.
  • 78 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q4 2018.

Based on FNY Investment Advisers's 13F filing for Q4 2018, filed 22 Jan 2019.